Rheumatology

Opinion: Incorporate Nocebo Planning Into IBD Treatment Strategy

September 3, 2020

Tony Hagen

Multiple studies indicate the nocebo effect is particularly influential in the treatment of inflammatory bowel disease (IBD), according to an opinion piece.

Bio-Thera Begins Phase 1 Trial for Ustekinumab Biosimilar

September 3, 2020

Skylar Jeremias

Article

Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.

Samsung Bioepis Exec Discusses European On-Ramp for Aybintio

September 3, 2020

Tony Hagen

Article

Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.

Report: PBM "Reforms" Leave Biosimilars Out in the Cold

September 2, 2020

Tony Hagen

Article

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

Biosimilar Developers and the Battle Against COVID-19

September 1, 2020

Skylar Jeremias

Article

A look at efforts biosimilar manufacturers are taking to develop treatments for coronavirus disease 2019 (COVID-19).

Biosimilar Rheumatology Roundup: August 2020

August 31, 2020

Skylar Jeremias

Article

The month of August was replete with clinical trial news and biosimilar launches for the treatment of rheumatic conditions.

Investigators Eye Gaps in Biosimilar Assessment Reports

August 31, 2020

Deana Ferreri, PhD

Article

Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.

Cadila Launches Fourth Biosimilar in 2 Months

August 29, 2020

Tony Hagen

Article

With the launch of an adalimumab, Cadila hopes to get a piece of the worldwide biosimilar market for antirheumatic treatments.

Updated "User's Guide" Published for Anti-TNFs in IBD

August 27, 2020

Deana Ferreri, PhD

Article

Two decades of using anti–tumor necrosis factor (TNF) drugs in inflammatory bowel disease (IBD) have answered some questions and left others unanswered.

Mylan, Lupin Launch Etanercept Biosimilar in Germany

August 27, 2020

Skylar Jeremias

Article

The launch marks the first European market entry for Nepexto.